Company intelligence / Profile preview

Neochromosome

New York City, New York, United Statesneochromosome.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Neochromosome has demonstrated the ability to design, synthesize, and deliver large segments of functional human genes into mammalian cells. Their platforms have been validated in multiple cell types including yeast, E. coli, and mammalian systems[1][3]. They collaborate with partners to accelerate protein drug discovery and manufacturing[4], but do not report clinical results for proprietary therapeutic programs.

Modalities: Gene therapyCell therapyRecombinant proteinAntibodyDNA synthesis
Industry: Drug Discovery Services

Partnerships

Sumitovant BiopharmaMekonos

Beyond the preview

Go deeper on Neochromosome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neochromosome.

Explore the full profile